Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Amubarvimab, an antibody targeting SARS-CoV-2 Spike RBD.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Rovelizumab, an antibody targeting ITGAL.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Epratuzumab, an antibody targeting SIGLEC2.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Visilizumab, an antibody targeting CD3E.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Pexelizumab, an antibody targeting C5.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Lerdelimumab, an antibody targeting TGFB1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Zanolimumab, an antibody targeting CD4.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Naptumomab, an antibody targeting TPBG.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Efungumab, an antibody targeting Heat Shock Protein 90 Homolog.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Abagovomab, an antibody targeting MUC16.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Tanezumab, an antibody targeting NGFB.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Farletuzumab, an antibody targeting Folate receptor alpha.